On December 21st, the Ukrainian Parliament voted in favor of legalizing medical cannabis, following a war with Russia that has resulted in thousands of people suffering from post-traumatic stress disorder. Many believe that this condition can be alleviated through medication, according to a report by the Associated Press.
The new law will come into effect six months from now, allowing for the scientific and industrial use of marijuana. It was passed in the Kiev Parliament with 248 votes out of the 401 seats. Details of the voting were not provided at the time. The law was proposed by Prime Minister Denys Smyhal.
The possibility of legalizing medical cannabis has been a long-standing debate in Ukraine. Many people endorse the benefits of cannabis for medical treatment, while others express concerns that legalizing medical marijuana may result in an influx of drugs into Ukrainian urban streets.
The measure imposes strict control over the production and sale of marijuana. Any medication containing cannabis derivatives requires a prescription from a doctor. The recreational use of marijuana remains classified as a criminal offense.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
